Rintatolimod

Chronic fatigue syndrome

For people with chronic fatigue syndrome, there is low quality evidence that rintatolimod can improve their ability to exercise.

Other uses

Rintatolimod is designed to boost cellular defenses against viruses and tumors, and can be used for avian influenza.

Side effects

An independent review of rintatolimod clinical trials in chronic fatigue syndrome was published in the December 2006 issue of the Journal of Clinical Virology. It concluded that Ampligen has been "generally well tolerated", with a "low incidence of clinical toxicity", particularly when compared with the toxicity of the diseases it is used to treat. "No serious safety issues have resulted from the administration of ~75,000 doses IV (most commonly 400 mg) twice weekly for up to one year periods or greater. Animal toxicity studies support this observation in humans, with primates demonstrating the greatest margin of safety." A mild flushing reaction has occurred in about 15% of patients, and more rarely reported side effects include chills, fever, malaise, leukopenia, neutropenia and leukocytosis. Some of these side effects may be attributed to a temporary Herxheimer reaction in response to pathogen die off. According to Hemispherx and patient testimonials, side-effects, when they occur, usually subside within three to four months or less.

Mechanism of action

One mode of action of this drug is to protect and stimulate the innate immune system, also called the nonspecific immune system, and the first line of defense. According to a study published in the Journal of Immunology and reflected in a press release by Hemispherx, Rintatolimod protects and stimulates the innate immune system by binding to Toll-like receptors 3 (TLR-3), and activating the TLR-3 receptors for broad-spectrum immune response. TLR-3 receptors are located on cell surfaces. They are part of a family of "pattern recognition" receptors that detect pathogens immediately, even those the body has not yet encountered, long before adaptive immunity can intervene against foreign invaders. These receptors are critical to the first line of immunological defense against a broad range of pathogens, including otherwise lethal viruses and various forms of cancer. When, for example, double-stranded RNA molecules from an RNA viral infection bind to TLR-3 receptors, the virus in this way inactivates the innate immune system, rendering it unable to signal the rest of the body's defenses. When rintatolimod binds to TLR-3 receptors, the virus cannot do so, and the body is able to marshal its defenses and launch an assault on the virus.

The mechanism of rintatolimod in relation to CFS is not certain, but is thought to include the RNase L enzyme. Rintatolimod is a dsRNA, and when TLR-3 senses a dsRNA, it is thought to relay a message to cells to produce interferons (IFNs). IFNs are a group of signaling molecules released by cells in response to the presence of pathogenic viruses or bacteria. These signaling molecules activate (among other things) the protective defenses of the immune system that eradicate pathogens. One such defense mechanism thought to be activated by rintatolimod is the production of the enzyme RNase L. This enzyme degrades pathogenic RNA, both viral and cellular. Degradation of RNA prevents viral and cell replication, and destruction of all RNA within a virus or cell is the last step before apoptosis or death. Accumulation of an inactive form of RNase L may be associated with CFS.

History

Rintatolimod development evolved from a 1960s synthesis by Merck & Co., a double-stranded RNA compound of inosinic and cytidylic acid residues (poly I:poly C or poly I:C). Poly I:C inhibited tumor growth by inducing interferon production, but was too toxic to use. In the mid-1970s, William A. Carter, a post-doctoral researcher at Johns Hopkins University, modified the dsRNA molecule by adding uridylic acid molecules at specific intervals along the RNA chain. The new compound, called Ampligen (for AMPLIfied GENetic activity) stimulated interferon production like poly I:C, but with much lower toxicity. It is also known as "poly I:poly C12U".

Dr. Carter founded a company based upon the compound, and licensed it from Johns Hopkins. By the late 1980s, Carter and his company, HEM Research, Inc., were pursuing human therapeutic uses for rintatolimod, as well as non-therapeutic uses, such as diagnostic testing for HIV and protecting plants from pathogens.

Rintatolimod was tested in clinical trials in the United States beginning in 1988, after DuPont invested $30 million in Hemispherx. Initial success in a small trial for AIDS treatment was followed by difficulties in persuading the FDA to permit large scale trials. By 1991, it was thought that the chance of approval for a large trial being conducted in the USA had gone. Hemispherx then began to move clinical trials to Canada and Belgium.

In Belgium, rintatolimod has been available for use since the drug's trial beginning in May 1996. It has also been available under Canada's Emergency Drug Release Program for both chronic fatigue syndrome (CFS) and HIV treatment since 1996, with marketing rights controlled by Biovail Corporation International. An agreement between the Spanish company Esteve and Hemispherx in 2002 gave Esteve the rights to perform clinical trials at their own cost in Spain, Portugal, and Andorra. Bioclones (PTY) Ltd, a UK based company, was granted the exclusive marketing rights to rintatolimod in the United Kingdom, Ireland, and several countries in the Southern Hemisphere. The marketing agreement with Bioclones was terminated in 2005. Over its developmental history, rintatolimod has received various designations, including "orphan drug product" and "emergency compassionate cost recovery sales authorization," both from the FDA, and "promising" clinical outcome recognition based on the evaluation of certain summary clinical reports (AHRQ, Agency Health Research Quality).

According to the US National Academy of Sciences Institute of Medicine, "Chronic Fatigue Syndrome is a disease characterized by profound fatigue, cognitive dysfunction, sleep abnormalities, autonomic manifestations, pain, and other symptoms that are made worse by exertion of any sort. CFS can severely impair patients’ ability to conduct their normal lives." In October 2007, Hemispherx BioPharma submitted their first New Drug Application (NDA) to the FDA for rintatolimod to treat CFS. In December 2007, the agency deemed the application incomplete, citing deficiencies including lack of dose ranging, statistical analysis plans inconsistent with protocols, database discrepancies, and lack of clinical pharmacology and carcinogenicity data. In early 2009, Hemispherx again submitted rintatolimod for FDA approval for CFS treatment. The FDA scheduled their decision for May 25th of that year and twice postponed. The company received a Complete Response Letter from the agency on rintatolimod's NDA in December 2009, requesting further data.

In 2007, and again during the 2009 swine flu outbreak, Carter said that rintatolimod could also be used as an H1N1 flu vaccine booster, citing in vitro studies with Ampligen and neuraminidase inhibitors oseltamivir and zanamivir (brand names Tamiflu and Relenza).

Hemispherx Biopharma continues to work with the FDA on rintatolimod approval for CFS treatment. On December 20, 2012, an FDA Advisory Committee voted in favor of rintatolimod's safety for commercial use (vote 8 to 5), but not in favor of its efficacy (4 to 9). The Complete Response Letter asked for more study data prior to rintatolimod approval. Recently, on January 12, 2015, the company released new in vitro study findings showing that low natural killer cell function associates with greater CFS disease symptom severity, and that rintatolimod treatment increases average NK cell activity over 100%. The new study report, "Low Natural Killer (NK) Activity Observed Across the Chronic Fatigue Syndrome (CFS) Disease Spectrum," has been submitted as a scientific paper for peer-review and publication. In addition to the new study findings, the paper summarizes 6 supportive publications of results with more than 150 CFS patients, correlating increased debility of CFS and low NK cell activity. Clinical testing is currently under way to determine whether NK cell activity augmentation by rintatolimod in vivo associates with lessened CFS disease severity and increased physical endurance and performance measures.

Controversy

Twice, in 1998 and 2000, Hemispherx received notices of violation from the FDA for promoting rintatolimod as safe and effective before FDA approval, in violation of the Federal Food, Drug, and Cosmetic Act.

Also in the late 1990s, Manuel Asensio, a notorious short seller and former investment banker since expelled from the securities industry, reported on Hemispherx, saying the company was overvalued. He criticized Hemispherx and its rintatolimod results, alleging a variety of misdemeanors, including accusations of refusing to supply rintatolimod after clinical trials have ended, and issuing misleading results to widen markets for rintatolimod.

In 1998, Hemispherx Biopharma filed a complaint against Asensio and his company, alleging defamation, conspiracy and interference with its business relations through a short-selling plot. After a jury rejected the defamation claims against Asensio, a mistrial was declared.

The following year, on November 2, 1999, Mary Schweitzer, a chronic fatigue syndrome patient who had been treated with rintatolimod, raised the question of why Ampligen has never been fast-tracked by the US public health authorities at the Chronic Fatigue Syndrome Co-ordinating Committee of the U.S. Department of Health and Human Services. Grassroots activism for FDA approval of Ampligen grew and continues. Current efforts in 2015 to spur FDA approval of Ampligen include petitions, appeal for congressional hearing, and popular social media group organizing.

Digital stock advisory The Street journalist, Adam Feuerstein, has published articles harshly critical of Hemispherx BioPharma, Inc. for over half a decade. In June 2009, Mr. Feuerstein alleged the company was "seeking to divert investors' attention away from the delayed approval of Ampligen as a treatment for chronic fatigue syndrome" by issuing three press releases in seven days about research from 2007 into possible applications for Ampligen as a flu vaccine booster, in which Hemispherx stated that Ampligen could be used against the H1N1 swine flu. This article also alleged the press releases were misleading, because they implied the research had been done in 2009. When Hemispherx offered Ampligen as a potential H1N1 vaccine or vaccine booster, the U.S. government turned them down, and Mr. Feuerstein wrote, "Hemispherx Biopharma has been shut out of the U.S. government's efforts to stockpile vaccine against the H1N1 flu." Mr. Feuerstein's subsequent articles on Hemispherx BioPharma for TheStreet.com|The Street continue to run in a similar vein.

Research

Rintatolimod has been studied in humans since 1994. In early 2015, the AMP 511 open-label study of rintatolimod in CFS was still recruiting participants. Open-label studies are typically used when the controlled trial has ended and treatment is continued so that the subjects and the controls may continue to receive the investigational drug until marketing approval is obtained. Hemispherx management had missed several target deadlines for new drug application (NDA) filing in the past, including the end of 2005, the third quarter of 2006, and the first quarter of the year 2007. In October 2007, the US Food and Drug Administration (FDA) Ampligen NDA was filed. In December 2009, the FDA issued a Complete Response Letter (CRL) refusing Hemispherx's new drug application for rintatolimod's treatment of CFS. The FDA concluded that the two RCTs "did not provide credible evidence of efficacy." The agency recommended a minimum of one additional six-month, 300-patient study, and rodent carcinogenicity studies.

Studies, including CFS studies, are ongoing. On January 12, 2015, the company announced rintatolimod has been found to improve NK cell function in human CFS patients.

Rintatolimod is administered intravenously. It is generally administered twice weekly for periods of one year or longer. Two toxicology studies had been completed as of 2007,which established the safety of intranasal and intramucosal methods of Ampligen administration as a vaccine immunostimulant. Hemispherx has conducted research on oral versions of Rintatolimod using nucleic acid technology related to rintatolimod.